FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gary Zurenko

Research Profile

Procedures

Microbial Sensitivity Tests

Chemicals & Drugs

Concepts & Ideas

Structure-Activity Relationship

Living Beings

Physiology

Bacterial Drug Resistance

Genes & Molecular Sequences

Molecular Structure

Disorders

Co-author Network

Publications

TOP 3
Wolfgang Haas; Chris M Pillar; Gary E Zurenko; Jacqueline C Lee; Lynne S Brunner; Timothy W Morris
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Cory Stiff; David R Graber; Atli Thorarensen; Brian D Wakefield; Keith Marotti; Earline P Melchior; Michael T Sweeney; Fusen Han; Douglas C Rohrer; Gary E Zurenko; Donna L Romero
Bacterial translation inhibitors, 1-acylindazol-3-ols as anthranilic acid mimics.
Alita A Miller; Gordon L Bundy; John E Mott; Jill E Skepner; Timothy P Boyle; Douglas W Harris; Alexander E Hromockyj; Keith Marotti; Gary E Zurenko; Jennifer B Munzner; Michael T Sweeney; Gary F Bammert; Judith C Hamel; Charles W Ford; Wei-Zhu Zhong; David R Graber; Gary E Martin; Fusen Han; Lester A Dolak; Eric P Seest; J Craig Ruble; Gregg M Kamilar; John R Palmer; Lee S Banitt; Alexander R Hurd; Michael R Barbachyn
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gary Zurenko (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Wolfgang Haas; Chris M Pillar; Gary E Zurenko; Jacqueline C Lee; Lynne S Brunner; Timothy W Morris
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Antimicrobial agents and chemotherapy 2009;53(8):3552-60.
2008: Cory Stiff; David R Graber; Atli Thorarensen; Brian D Wakefield; Keith Marotti; Earline P Melchior; Michael T Sweeney; Fusen Han; Douglas C Rohrer; Gary E Zurenko; Donna L Romero
Bacterial translation inhibitors, 1-acylindazol-3-ols as anthranilic acid mimics.
Bioorganic & medicinal chemistry letters 2008;18(23):6293-7.
2008: Alita A Miller; Gordon L Bundy; John E Mott; Jill E Skepner; Timothy P Boyle; Douglas W Harris; Alexander E Hromockyj; Keith Marotti; Gary E Zurenko; Jennifer B Munzner; Michael T Sweeney; Gary F Bammert; Judith C Hamel; Charles W Ford; Wei-Zhu Zhong; David R Graber; Gary E Martin; Fusen Han; Lester A Dolak; Eric P Seest; J Craig Ruble; Gregg M Kamilar; John R Palmer; Lee S Banitt; Alexander R Hurd; Michael R Barbachyn
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
Antimicrobial agents and chemotherapy 2008;52(8):2806-12.
2007: Toni-Jo Poel; Richard C Thomas; Wade J Adams; Paul A Aristoff; Michael R Barbachyn; Frederick E Boyer; Joan Brieland; Roger Brideau; Joanne Brodfuehrer; Alan P Brown; Allison L Choy; Michael R Dermyer; Michael Dority; Charles W Ford; Robert C Gadwood; Debra L Hanna; Cai Hongliang; Michael D Huband; Christopher Huber; Rose Kelly; Ji-Young Kim; Joseph P Martin; Paul J Pagano; Daniel Ross; Laura Skerlos; Mark C Sulavik; Tong Zhu; Gary E Zurenko; J V N Vara Prasad
Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.
Journal of medicinal chemistry 2007;50(24):5886-9.
2007: Cory M Stiff; Min Zhong; Ronald W Sarver; Hua Gao; Andrea M Ho; Michael T Sweeney; Gary E Zurenko; Donna L Romero
Correlation of carboxylic acid pKa to protein binding and antibacterial activity of a novel class of bacterial translation inhibitors.
Bioorganic & medicinal chemistry letters 2007;17(19):5479-82.
2007: J Craig Ruble; Brian D Wakefield; Gregg M Kamilar; Keith Marotti; Earline P Melchior; Michael T Sweeney; Gary E Zurenko; Donna L Romero
Structure-activity relationships of bioisosteres of a carboxylic acid in a novel class of bacterial translation inhibitors.
Bioorganic & medicinal chemistry letters 2007;17(14):4040-3.
2007: Atli Thorarensen; Jianke Li; Brian D Wakefield; Donna L Romero; Keith Marotti; Michael T Sweeney; Gary E Zurenko; Ronald W Sarver
Preparation of novel anthranilic acids as antibacterial agents: extensive evaluation of structural and physical properties on antibacterial activity and human serum albumin affinity.
Bioorganic & medicinal chemistry letters 2007;17(11):3113-6.
2007: Atli Thorarensen; Brian D Wakefield; Donna L Romero; Keith Marotti; Michael T Sweeney; Gary E Zurenko; Douglas C Rohrer; Fusen Han; Garold L Bryant
Preparation of novel anthranilic acids as antibacterial agents. Extensive evaluation of alternative amide bioisosteres connecting the A- and the B-rings.
Bioorganic & medicinal chemistry letters 2007;17(10):2823-7.
2007: Jianke Li; Brian D Wakefield; J Craig Ruble; Cory M Stiff; Donna L Romero; Keith Marotti; Michael T Sweeney; Gary E Zurenko; Douglas C Rohrer; Atli Thorarensen
Preparation of novel antibacterial agents. Replacement of the central aromatic ring with heterocycles.
Bioorganic & medicinal chemistry letters 2007;17(8):2347-50.
2004: Martin R Deibel; Alice L Bodnar; Anthony W Yem; Cindy L Wolfe; Charlotte L Heckaman; Michael J Bohanon; William Mathews; Michael T Sweeney; Gary E Zurenko; Keith Marotti; Timothy P Boyle; Atli Thorarensen
Immobilization of a novel antibacterial agent on solid phase and subsequent isolation of EF-Tu.
Bioconjugate chemistry 2004;15(2):333-43.
2003: Fred Ciske; Michael R Barbachyn; Michael J Genin; Kevin C Grega; Chi Sing Lee; Lester A Dolak; Eric P Seest; William Watt; Wade J Adams; Janice M Friis; Charles W Ford; Gary E Zurenko
The effect of remote chirality on the antibacterial activity of indolinyl, tetrahydroquinolyl and dihydrobenzoxazinyl oxazolidinones.
Bioorganic & medicinal chemistry letters 2003;13(23):4235-9.
2003: Mikhail F Gordeev; Corinne Hackbarth; Michael R Barbachyn; Lee S Banitt; James R Gage; Gary W Luehr; Marcela Gomez; Joaquim Trias; Sara E Morin; Gary E Zurenko; Christian N Parker; Jonathan M Evans; Richard J White; Dinesh V Patel
Novel oxazolidinone-quinolone hybrid antimicrobials.
Bioorganic & medicinal chemistry letters 2003;13(23):4213-6.
2003: Upinder Singh; B Raju; Stuart Lam; Joseph Zhou; Robert C Gadwood; Charles W Ford; Gary E Zurenko; Ronda D Schaadt; Sara E Morin; Wade J Adams; Janice M Friis; Maria Courtney; Joe Palandra; Corinne Hackbarth; Lopez Sara; Charlotte Wu; Kathleen H Mortell; Joaquim Trias; Zhengyu Yuan; Dinesh V Patel; Mikhail F Gordeev
New antibacterial tetrahydro-4(2H)-thiopyran and thiomorpholine S-oxide and S,S-dioxide phenyloxazolidinones.
Bioorganic & medicinal chemistry letters 2003;13(23):4209-12.
2003: Paul D Johnson; Paul A Aristoff; Gary E Zurenko; Ronda D Schaadt; Betty H Yagi; Charles W Ford; Judith C Hamel; Douglas Stapert; Judy K Moerman
Synthesis and biological evaluation of benzazepine oxazolidinone antibacterials.
Bioorganic & medicinal chemistry letters 2003;13(23):4197-200.
2003: Lisa M Thomasco; Robert C Gadwood; Elizabeth A Weaver; Jason M Ochoada; Charles W Ford; Gary E Zurenko; Judith C Hamel; Douglas Stapert; Judy K Moerman; Ronda D Schaadt; Betty H Yagi
The synthesis and antibacterial activity of 1,3,4-thiadiazole phenyl oxazolidinone analogues.
Bioorganic & medicinal chemistry letters 2003;13(23):4193-6.
2003: Michael T Sweeney; Gary E Zurenko
In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
Antimicrobial agents and chemotherapy 2003;47(6):1902-6.
2003: William R Humphrey; Mark H Shattuck; Raymond J Zielinski; Ming-Shang T Kuo; John J Biermacher; Donald P Smith; Jana L Jensen; Ronda D Schaadt; Gary E Zurenko; Ivan M Richards
Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media.
Antimicrobial agents and chemotherapy 2003;47(4):1355-63.
2003: Betty H Yagi; Gary E Zurenko
An in vitro time-kill assessment of linezolid and anaerobic bacteria.
Anaerobe 2003;9(1):1-3.
2003: Michael R Barbachyn; Gary J Cleek; Lester A Dolak; Stuart A Garmon; Joel Morris; Eric P Seest; Richard C Thomas; Dana S Toops; William Watt; Donn G Wishka; Charles W Ford; Gary E Zurenko; Judith C Hamel; Ronda D Schaadt; Douglas Stapert; Betty H Yagi; Wade J Adams; Janice M Friis; John Gregory Slatter; James Peter Sams; Nancee L Oien; Matthew J Zaya; Larry C Wienkers; Michael A Wynalda
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
Journal of medicinal chemistry 2003;46(2):284-302.
2001: C S Lee; DA Allwine; Michael R Barbachyn; Kevin C Grega; Lester A Dolak; Charles W Ford; RM Jensen; Eric P Seest; Judith C Hamel; Ronda D Schaadt; Douglas Stapert; Betty H Yagi; Gary E Zurenko; Michael J Genin
Carbon-carbon-linked (pyrazolylphenyl)oxazolidinones with antibacterial activity against multiple drug resistant gram-positive and fastidious gram-negative bacteria.
Bioorganic & medicinal chemistry 2001;9(12):3243-53.
2001: Atli Thorarensen; Gary E Zurenko; Michael T Sweeney; Keith Marotti; Timothy P Boyle
Enols as potent antibacterial agents.
Bioorganic & medicinal chemistry letters 2001;11(22):2931-4.
2001: Gary E Zurenko; John K Gibson; D L Shinabarger; Paul A Aristoff; Charles W Ford; WG Tarpley
Oxazolidinones: a new class of antibacterials.
Current opinion in pharmacology 2001;1(5):470-6.
2001: Charles W Ford; Gary E Zurenko; Michael R Barbachyn
The discovery of linezolid, the first oxazolidinone antibacterial agent.
Current drug targets. Infectious disorders 2001;1(2):181-99.
2001: Atli Thorarensen; A L Presley-Bodnar; Keith Marotti; Timothy P Boyle; C L Heckaman; Michael J Bohanon; Paul K Tomich; Gary E Zurenko; Michael T Sweeney; Betty H Yagi
3-Arylpiperidines as potentiators of existing antibacterial agents.
Bioorganic & medicinal chemistry letters 2001;11(14):1903-6.
2001: Atli Thorarensen; Martin R Deibel; Douglas C Rohrer; Anne F Vosters; Anthony W Yem; V D Marshall; JC Lynn; Michael J Bohanon; Paul K Tomich; Gary E Zurenko; Michael T Sweeney; RM Jensen; J W Nielsen; Eric P Seest; Lester A Dolak
Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition.
Bioorganic & medicinal chemistry letters 2001;11(11):1355-8.
2000: Michael J Genin; DA Allwine; D J Anderson; Michael R Barbachyn; DE Emmert; Stuart A Garmon; DR Graber; Kevin C Grega; JB Hester; DK Hutchinson; Joel Morris; R J Reischer; Charles W Ford; Gary E Zurenko; Judith C Hamel; Ronda D Schaadt; Douglas Stapert; Betty H Yagi
Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
Journal of medicinal chemistry 2000;43(5):953-70.
1998: Michael J Genin; DK Hutchinson; DA Allwine; JB Hester; DE Emmert; Stuart A Garmon; Charles W Ford; Gary E Zurenko; Judith C Hamel; Ronda D Schaadt; Douglas Stapert; Betty H Yagi; Janice M Friis; Eric M Shobe; Wade J Adams
Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
Journal of medicinal chemistry 1998;41(26):5144-7.
1998: J A Tucker; DA Allwine; Kevin C Grega; Michael R Barbachyn; J L Klock; J L Adamski; SJ Brickner; DK Hutchinson; Charles W Ford; Gary E Zurenko; RA Conradi; Philip S Burton; RM Jensen
Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
Journal of medicinal chemistry 1998;41(19):3727-35.
1998: D M Gleave; SJ Brickner; P R Manninen; DA Allwine; K D Lovasz; Douglas C Rohrer; J A Tucker; Gary E Zurenko; Charles W Ford
Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
Bioorganic & medicinal chemistry letters 1998;8(10):1231-6.
1998: RW Murray; Ronda D Schaadt; Gary E Zurenko; Keith Marotti
Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay.
Antimicrobial agents and chemotherapy 1998;42(4):947-50.
1998: Michael R Barbachyn; SJ Brickner; Robert C Gadwood; Stuart A Garmon; Kevin C Grega; DK Hutchinson; K Munesada; R J Reischer; M Taniguchi; Lisa M Thomasco; D S Toops; H Yamada; Charles W Ford; Gary E Zurenko
Design, synthesis, and evaluation of novel oxazolidinone antibacterial agents active against multidrug-resistant bacteria.
Advances in experimental medicine and biology 1998;456():219-38.
1997: Betty H Yagi; Gary E Zurenko
In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria.
Anaerobe 1997;3(5):301-6.
1997: Ronda D Schaadt; Donald H Batts; Peter Daley-Yates; S D Pawsey; Dennis J Stalker; Gary E Zurenko
Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid.
Diagnostic microbiology and infectious disease 1997;28(4):201-4.
1997: Charles W Ford; Judith C Hamel; Douglas Stapert; Judy K Moerman; DK Hutchinson; Michael R Barbachyn; Gary E Zurenko
Oxazolidinones: new antibacterial agents.
Trends in microbiology 1997;5(5):196-200.
1997: Gary E Zurenko; Charles W Ford; DK Hutchinson; SJ Brickner; Michael R Barbachyn
Oxazolidinone antibacterial agents: development of the clinical candidates eperezolid and linezolid.
Expert opinion on investigational drugs 1997;6(2):151-8.
1996: Gary E Zurenko; Betty H Yagi; Ronda D Schaadt; J W Allison; J O Kilburn; S E Glickman; DK Hutchinson; Michael R Barbachyn; SJ Brickner
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
Antimicrobial agents and chemotherapy 1996;40(4):839-45.
1996: Michael R Barbachyn; DK Hutchinson; SJ Brickner; Michael H Cynamon; J O Kilburn; S P Klemens; S E Glickman; Kevin C Grega; S K Hendges; D S Toops; Charles W Ford; Gary E Zurenko
Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.
Journal of medicinal chemistry 1996;39(3):680-5.
1996: SJ Brickner; DK Hutchinson; Michael R Barbachyn; P R Manninen; D A Ulanowicz; Stuart A Garmon; Kevin C Grega; S K Hendges; D S Toops; Charles W Ford; Gary E Zurenko
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
Journal of medicinal chemistry 1996;39(3):673-9.
1992: Betty H Yagi; Ronda D Schaadt; Gary E Zurenko
The bactericidal activity and postantibiotic effect of trospectomycin.
Diagnostic microbiology and infectious disease 1992;15(5):417-23.
1992: M N Brunden; Gary E Zurenko; B Kapik
Modification of the error-rate bounded classification scheme for use with two MIC break points.
Diagnostic microbiology and infectious disease 1992;15(2):135-40.
1992: SJ Brickner; J J Gaikema; Gary E Zurenko; L J Greenfield; P R Manninen; D A Ulanowicz
N-acyl 3-alkylidenyl- and 3-alkyl azetidin-2-ones: a new class of monocyclic beta-lactam antibacterial agents. 1. Structure-activity relationships of 3-isopropylidene and 3-isopropyl analogs.
The Journal of antibiotics 1992;45(2):213-26.
1991: M N Brunden; Betty H Yagi; M S Lajiness; Gary E Zurenko
Estimating the postantibiotic effect: a two-phase mathematical model.
Journal of pharmacokinetics and biopharmaceutics 1991;19(4):457-68.
1990: E Novak; L M Paxton; A Bye; R Patel; Gary E Zurenko; S F Francom
Human safety and pharmacokinetics of a single intramuscular dose of a novel spectinomycin analog, trospectomycin (U-63,366F).
Antimicrobial agents and chemotherapy 1990;34(12):2342-7.
1990: A R Euler; Gary E Zurenko; J B Moe; R G Ulrich; Y Yagi
Evaluation of two monkey species (Macaca mulatta and Macaca fascicularis) as possible models for human Helicobacter pylori disease.
Journal of clinical microbiology 1990;28(10):2285-90.
1990: Gary E Zurenko; S E Truesdell; Betty H Yagi; R J Mourey; Alice Laborde
In vitro antibacterial activity and interactions with beta-lactamases and penicillin-binding proteins of the new monocarbam antibiotic U-78608.
Antimicrobial agents and chemotherapy 1990;34(5):884-8.
1990: Ronda D Schaadt; Betty H Yagi; Gary E Zurenko
In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae.
Antimicrobial agents and chemotherapy 1990;34(2):371-2.
1989: S E Truesdell; Gary E Zurenko; Alice Laborde
Interaction of cephalosporins with penicillin-binding proteins of methicillin-resistant Staphylococcus aureus.
The Journal of antimicrobial chemotherapy 1989;23 Suppl D():13-9.
1988: Gary E Zurenko; Betty H Yagi; J J Vavra; B B Wentworth
In vitro antibacterial activity of trospectomycin (U-63366F), a novel spectinomycin analog.
Antimicrobial agents and chemotherapy 1988;32(2):216-23.
1988: Gary E Zurenko; Charles W Ford; E Novak
Trospectomycin, a novel spectinomycin analogue: antibacterial activity and preliminary human pharmacokinetics.
Drugs under experimental and clinical research 1988;14(6):403-9.